Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | KLKB1 | P03952 | 16/20 | 0.38 |
| ▸ | MAP4K1 | Q92918 | 12/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | TEC | P42680 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28098263 | 0.77 | KLKB1 (0.39) | KLKB1MAP4K1TEC | |
| SCHEMBL4049830 | 0.77 | ALDH1A1 (0.46) | METPDE10A | |
| SCHEMBL21190199 | 0.76 | KLKB1 (0.41) | KLKB1MAP4K1 | |
| SCHEMBL22276493 | 0.76 | CYP1A2 (0.41) | KLKB1MAP4K1 | |
| SCHEMBL31663279 | 0.75 | HTR3A (0.40) | METPDE10ATEC | |
| SCHEMBL17442812 | 0.74 | KLKB1 (0.42) | KLKB1MAP4K1 | |
| SCHEMBL554212 | 0.72 | KLKB1 (0.44) | KLKB1MAP4K1 | |
| Hydrochloric Acid SCHEMBL28309817 | 0.72 | KLKB1 (0.41) | KLKB1MAP4K1 | |
| SCHEMBL21190208 | 0.72 | ALDH1A1 (0.47) | KLKB1MAP4K1 | |
| SCHEMBL20919413 | 0.72 | KDM4E (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9290485-B2 | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides | NOVARTIS AG (CH) | 2016-03-22 | — | — | US | disclosed |
| EP-2601189-B1 | N-((6-AMINO-PYRIDIN-3-YL)METHYL)-HETEROARYL-CARBOXAMIDES AS INHIBITORS OF PLASMA KALLIKREIN | NOVARTIS AG (CH) | 2015-04-15 | — | — | EP | disclosed |
| EP-2601189-A1 | N-((6-AMINO-PYRIDIN-3-YL)METHYL)-HETEROARYL-CARBOXAMIDES AS INHIBITORS OF PLASMA KALLIKREIN | Novartis AG (CH) | 2013-06-12 | — | — | EP | disclosed |
| US-20120035168-A1 | N-((6-AMINO-PYRIDIN-3-YL)METHYL)-HETEROARYL-CARBOXAMIDES | NOVARTIS AG (CH) | 2012-02-09 | — | — | US | disclosed |
| WO-2012017020-A1 | N-((6-AMINO-PYRIDIN-3-YL)METHYL)-HETEROARYL-CARBOXAMIDES AS INHIBITORS OF PLASMA KALLIKREIN | NOVARTIS AG (CH) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035168-A1 | N-((6-AMINO-PYRIDIN-3-YL)METHYL)-HETEROARYL-CARBOXAMIDES | TPMT, REN, PNMT | MET 987/4885KLKB1 4526/4885MAP4K1 1432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.